A Comprehensive Scientific Review

Abstract

Crohn's Disease (CD) represents a significant clinical challenge characterized by chronic inflammation, immune dysregulation, and reduced quality of life. While conventional pharmacological interventions remain the cornerstone of treatment, emerging evidence suggests that far infrared (FIR) therapy may serve as a valuable adjunctive approach. This review examines the mechanistic basis, preclinical evidence, and clinical applications of FIR therapy in the context of inflammatory bowel disease, with specific focus on its potential benefits for athletes and high-performance individuals managing Crohn's Disease.

Introduction

Crohn's Disease is a chronic, relapsing inflammatory bowel disease affecting approximately 3 million Americans, characterized by transmural intestinal inflammation, immune system dysfunction, and systemic manifestations including fatigue, malnutrition, and reduced exercise tolerance (Kaplan, 2015). The condition presents unique challenges for athletes and individuals in high-performance environments, where optimal recovery, reduced inflammation, and sustained energy levels are crucial for success.

Traditional therapeutic approaches, including corticosteroids, immunomodulators, and biologic agents, while effective in managing disease activity, often carry significant side effects that may impair athletic performance and overall quality of life (Torres et al., 2019). This has led to increased interest in complementary therapeutic modalities that can address the underlying inflammatory processes while minimizing adverse effects.

Far infrared therapy, utilizing electromagnetic radiation in the 3-1000 μm wavelength range, has emerged as a promising adjunctive treatment modality with demonstrated anti-inflammatory, circulatory, and metabolic benefits (Shui et al., 2015). The therapeutic potential of FIR in inflammatory conditions stems from its ability to penetrate tissues to depths of 2-5 in., influencing cellular processes at the mitochondrial level while promoting systemic physiological adaptations.

Pathophysiology of Crohn's Disease and Therapeutic Targets

Crohn's Disease pathogenesis involves a complex interplay of genetic predisposition, environmental triggers, intestinal barrier dysfunction, and dysregulated immune responses (Khor et al., 2011). Key pathophysiological features include:

• Chronic Inflammation: Overproduction of pro-inflammatory cytokines, particularly TNF-α, IL-6, and IL-1β, leading to sustained tissue damage and impaired healing (Neurath, 2014).

• Immune Dysregulation: Inappropriate Th1 and Th17 cell responses with inadequate regulatory T-cell function (Imam et al., 2018).

• Intestinal Barrier Dysfunction: Compromised epithelial integrity leading to increased permeability and bacterial translocation (Zeissig et al., 2007).

• Microvascular Impairment: Reduced tissue perfusion and oxygenation in affected intestinal segments (Hatoum et al., 2003).

• Mitochondrial Dysfunction: Impaired cellular energy metabolism contributing to fatigue and reduced tissue repair capacity (Boyapati et al., 2017).

These pathophysiological mechanisms represent potential therapeutic targets for FIR intervention, offering opportunities for multi-modal treatment approaches that complement conventional pharmacotherapy.

Mechanisms of Far Infrared Therapy in Inflammatory Bowel Disease

1. Anti-Inflammatory Effects

Far infrared radiation exerts potent anti-inflammatory effects through multiple pathways relevant to Crohn's Disease pathogenesis. FIR treatment can inhibit or reduce IL-6 and TNF-α activity (Lin et al., 2018), two critical pro-inflammatory cytokines central to IBD pathophysiology. The mechanism involves modulation of nuclear factor-κB (NF-κB) signaling pathways, leading to reduced transcription of inflammatory genes (Yu et al., 2006).

Exposure to FIR attenuates TNFα-induced adhesion molecule E-selectin, vascular cell adhesion protein-1, and monocyte chemoattractant protein-1 (Lai et al., 2020). This reduction in adhesion molecules and chemotactic factors may help limit inflammatory cell recruitment to intestinal tissues, potentially reducing the severity of local inflammatory responses.

The anti-inflammatory effects of FIR therapy extend beyond cytokine modulation to include enhanced production of anti-inflammatory mediators and improved cellular stress responses. Studies demonstrate that FIR exposure can increase heat shock protein expression, which serves as a cytoprotective mechanism against inflammatory damage (Akasaki et al., 2006).

2. Enhanced Microcirculation and Tissue Oxygenation

Microvascular dysfunction is a hallmark of Crohn's Disease, contributing to tissue hypoxia and impaired healing responses. FIR therapy promotes significant improvements in endothelial function and tissue perfusion through several mechanisms:

• Vasodilation: FIR exposure induces nitric oxide (NO) release from endothelial cells, promoting smooth muscle relaxation and increased vessel diameter (Imamura et al., 2001).

• Endothelial Function: FIR therapy can stabilize eNOS expression (Lin et al., 2018), supporting sustained nitric oxide production and vascular health.

• Rheological Improvements: Enhanced red blood cell deformability and reduced plasma viscosity contribute to improved tissue perfusion (Ernst et al., 1990).

For athletes with Crohn's Disease, improved microcirculation translates to enhanced nutrient delivery, better oxygen utilization, and accelerated recovery from both disease-related tissue damage and exercise-induced stress.

3. Mitochondrial Function and Energy Metabolism

Mitochondrial dysfunction represents a significant contributor to the fatigue and reduced exercise tolerance commonly observed in Crohn's Disease patients. FIR therapy addresses this through direct effects on mitochondrial biogenesis and function:

• Cytochrome c Oxidase Activation: FIR radiation specifically targets complex IV of the electron transport chain, enhancing ATP production efficiency (Karu, 1999).

• Mitochondrial Biogenesis: Increased expression of PGC-1α and other transcriptional regulators promotes new mitochondrial synthesis (Huang et al., 2012).

• Oxidative Stress Reduction: Enhanced antioxidant enzyme activity helps protect mitochondria from inflammatory damage (Leung et al., 2011).

These metabolic improvements may be particularly beneficial for high-performance individuals, supporting sustained energy levels and improved recovery capacity during training and competition periods.

4. Autonomic Nervous System Modulation

The gut-brain axis plays a crucial role in IBD pathogenesis, with psychological stress serving as a well-recognized trigger for disease flares. FIR therapy demonstrates beneficial effects on autonomic nervous system balance:

• Sympathetic Nervous System: Regular FIR sauna use reduces sympathetic overdrive, as evidenced by decreased norepinephrine levels and heart rate variability improvements (Ohori et al., 2012).

• Parasympathetic Activation: Enhanced vagal tone supports digestive function and anti-inflammatory pathways through the cholinergic anti-inflammatory reflex (Munford & Tracey, 2002).

• Stress Hormone Modulation: Reduced cortisol and inflammatory marker levels following FIR treatment suggest improved stress resilience (Matsumoto et al., 2011).

For athletes managing Crohn's Disease, these autonomic improvements may help maintain disease remission during periods of intense training stress and competition pressure.

Preclinical Evidence

Animal Model Studies

Preclinical research has provided valuable insights into the mechanisms and efficacy of infrared light therapy in inflammatory bowel disease models:

Light-emitting diodes at 940 nm attenuate colitis-induced inflammatory process in mice (de Brito et al., 2016), demonstrating that near-infrared wavelengths can effectively reduce intestinal inflammation in experimental colitis models.

LED treatment decreased the amount of crypt dysplasia/edema, inflammatory infiltrates and ulcers, attenuated apoptosis and increased proliferation of crypt cells (Marques et al., 2020). This study showed that red light treatment improved tissue recovery in DSS-induced colitis, suggesting potential benefits for intestinal healing in IBD.

Additional preclinical studies have demonstrated:

• Improved intestinal barrier function with reduced permeability (Sanderson et al., 2008)

• Enhanced epithelial cell proliferation and wound healing (Peplow et al., 2010)

• Modulation of immune cell populations in gut-associated lymphoid tissue (Avci et al., 2013)

• Reduction in oxidative stress markers in intestinal tissues (Hamblin, 2017)

Mechanistic Studies

Laboratory investigations have elucidated several key mechanisms underlying FIR's therapeutic effects:

1. Cellular Energy Production: FIR exposure increases ATP synthesis in intestinal epithelial cells, supporting enhanced repair and barrier function (Chen et al., 2014).

2. Heat Shock Protein Induction: Mild hyperthermia from FIR treatment stimulates cytoprotective heat shock proteins, enhancing cellular resilience to inflammatory stress (Kregel, 2002).

3. Nitric Oxide Signaling: FIR therapy enhances endothelial nitric oxide synthase activity, promoting vasodilation and anti-inflammatory signaling (Shang et al., 2013).

Clinical Evidence in Related Conditions

While direct clinical trials specifically examining FIR therapy in Crohn's Disease remain limited, substantial evidence exists for its therapeutic benefits in related inflammatory conditions:

Cardiovascular Disease

FIRS treatment improved cardiac function and clinical symptoms in those with CHF and that this improvement was the result of improved vascular endothelial function (Beever, 2009). Multiple studies have demonstrated FIR's ability to improve endothelial function, reduce blood pressure, and enhance exercise tolerance in cardiovascular patients.

Chronic Inflammatory Conditions

Studies in rheumatoid arthritis, fibromyalgia, and chronic fatigue syndrome have shown:

• Significant reductions in pain and fatigue scores (Matsumoto et al., 2011)

• Improved functional capacity and quality of life measures (Oosterveld et al., 2009)

• Decreased inflammatory markers including C-reactive protein and ESR (Uddin et al., 2020)

Photobiomodulation in IBD

Photobiomodulation is finding a niche in the treatment of conditions that have no gold-standard treatment or only partially effective (Liebert et al., 2023). Recent research has explored photobiomodulation's potential for addressing IBD-related symptoms:

• Fatigue Management: Studies suggest that light therapy may help address the chronic fatigue commonly experienced by IBD patients through mitochondrial enhancement (Hamblin, 2018).

• Pain Reduction: Anti-inflammatory effects of phototherapy may contribute to reduced abdominal pain and discomfort (Chow et al., 2007).

• Mood Improvements: Light therapy's effects on neurotransmitter balance may help address depression and anxiety frequently comorbid with IBD (Lam et al., 2006).

Current Clinical Trials and Emerging Evidence

The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients (Clinical Trial, 2023). This ongoing investigation represents one of the first direct examinations of FIR therapy specifically in Crohn's Disease patients, with participants receiving 10 treatments while researchers monitor biomarkers and symptom changes.

Preliminary observations from clinical practice and case reports suggest:

• Improved symptom control in patients using adjunctive FIR therapy

• Enhanced quality of life scores during treatment periods

• Better tolerance of conventional medications when combined with FIR

• Reduced frequency of disease flares in some individuals

Applications for High-Performance Athletes

Athletes with Crohn's Disease face unique challenges requiring specialized therapeutic approaches that support both disease management and performance optimization:

Performance-Specific Benefits

1. Enhanced Recovery: Improved circulation and reduced inflammation may accelerate recovery from training sessions and competitions.

2. Fatigue Management: Mitochondrial enhancement through FIR therapy may help counter IBD-related fatigue that limits training capacity.

3. Stress Resilience: Autonomic nervous system improvements may help athletes maintain disease remission during high-stress competition periods.

4. Non-Pharmaceutical Approach: FIR therapy offers therapeutic benefits without medication-related side effects that might impact performance or testing protocols.

Integration with Training Programs

FIR therapy can be integrated into athletic training regimens through:

• Pre-training Preparation: Brief FIR exposure may enhance circulation and prepare tissues for exercise stress

• Post-exercise Recovery: Extended FIR sessions following training may accelerate inflammatory resolution and tissue repair

• Maintenance Therapy: Regular FIR treatments during off-season periods may help maintain disease remission and baseline fitness

Safety Considerations and Contraindications

FIR therapy demonstrates an excellent safety profile with minimal reported adverse effects:

General Safety

• Well-tolerated in most individuals with rare side effects

• No significant drug interactions with conventional IBD medications

• Minimal risk of thermal injury when used according to manufacturer guidelines

Specific Considerations for IBD Patients

• Active Inflammation: While generally safe, patients with severe active disease should consult healthcare providers before initiating therapy

• Medication Interactions: No known interactions with biologics, immunosuppressants, or other IBD medications

• Hydration Status: Adequate fluid intake is important during FIR sessions, particularly relevant for IBD patients prone to dehydration

Athletic Considerations

• Competition Scheduling: FIR treatments should be timed appropriately around competition schedules

• Drug Testing: FIR therapy poses no risk for anti-doping violations

• Performance Monitoring: Athletes should track both disease markers and performance metrics during FIR therapy implementation

Practical Implementation

Treatment Protocols

Based on available evidence and clinical experience, effective FIR therapy protocols for Crohn's Disease typically include:

Frequency: 3-5 sessions per week during initial treatment phases, reducing to 2-3 sessions for maintenance

Duration: 15-30 minutes per session, depending on individual tolerance and device specifications

Wavelength: Far infrared range (7-14 μm) at a power density of 40 mW/cm² for optimal tissue penetration

Device Options

1. Far Infrared Saunas: Full-body exposure systems suitable for comprehensive treatment

2. Portable FIR Devices: Targeted treatment options for specific body regions

3. FIR Clothing and Textiles: Continuous low-level exposure options for daily use

4. Professional Clinical Units: Higher-powered systems available in healthcare settings

Integration with Conventional Care

FIR therapy should be implemented as an adjunctive treatment alongside established medical management:

• Communication with Healthcare Team: All FIR therapy should be discussed with gastroenterologists and healthcare providers

• Monitoring Parameters: Regular assessment of disease activity markers, symptoms, and quality of life

• Medication Compliance: FIR therapy supplements rather than replaces conventional treatments

• Lifestyle Factors: Integration with appropriate diet, stress management, and exercise protocols

Future Research Directions

Several areas warrant further investigation to establish FIR therapy's role in IBD management:

Clinical Trials Needed

1. Randomized Controlled Studies: Large-scale RCTs specifically examining FIR therapy in Crohn's Disease and ulcerative colitis populations

2. Dose-Response Relationships: Optimization of treatment parameters including frequency, duration, and intensity

3. Long-term Outcomes: Extended follow-up studies assessing disease progression and remission maintenance

4. Athletic Populations: Specific studies in athletes with IBD examining performance and disease outcomes

Mechanistic Research

1. Biomarker Development: Identification of specific inflammatory markers responsive to FIR therapy

2. Genetic Factors: Investigation of patient characteristics predicting FIR therapy response

3. Combination Therapies: Synergistic effects with conventional medications and other complementary approaches

4. Optimal Dosing: Determination of minimal effective doses and maximum safe exposures

Technology Development

1. Targeted Delivery Systems: Development of devices specifically designed for intestinal applications

2. Monitoring Integration: Real-time assessment of treatment response and optimization

3. Portable Solutions: Enhanced accessibility for athlete and patient populations

4. Combination Modalities: Integration with other light therapy wavelengths or treatment modalities

Economic Considerations

The economic impact of FIR therapy in IBD management deserves consideration, particularly in athletic populations:

Cost-Effectiveness Factors

• Reduced Medication Costs: Potential for decreased pharmaceutical expenditures through improved disease control

• Healthcare Utilization: Possible reduction in hospitalization and emergency care needs

• Performance Benefits: Economic value of maintained athletic performance and career longevity

• Quality of Life: Improved functional status and reduced disability-related costs

Implementation Costs

• Initial Equipment Investment: Upfront costs for FIR devices and infrastructure

• Maintenance and Operating Costs: Ongoing expenses for device operation and maintenance

• Training and Support: Healthcare provider education and patient instruction requirements

• Insurance Coverage: Current limitations in coverage for complementary therapies

Conclusion

Far infrared therapy represents a promising adjunctive treatment modality for Crohn's Disease, offering multiple therapeutic mechanisms that address key pathophysiological features of the condition. The therapy's anti-inflammatory effects, circulatory improvements, mitochondrial enhancement, and autonomic nervous system modulation provide a compelling rationale for its integration into comprehensive IBD management strategies.

For athletes and high-performance individuals managing Crohn's Disease, FIR therapy offers particular advantages through its non-pharmaceutical approach, performance-supporting mechanisms, and excellent safety profile. The ability to enhance recovery, reduce fatigue, and potentially maintain disease remission during periods of training and competition stress makes FIR therapy an attractive option for this population.

Current evidence, while encouraging, highlights the need for additional clinical research specifically examining FIR therapy in IBD populations. Ongoing clinical trials testing the safety and efficacy of far Infra-red therapy in Crohn's disease patients represent important steps toward establishing evidence-based protocols for this promising therapeutic approach.

The integration of FIR therapy into IBD management requires careful coordination with conventional medical care, appropriate patient selection, and ongoing monitoring of treatment responses. As our understanding of FIR therapy's mechanisms and optimal applications continues to evolve, this modality may become an increasingly valuable component of personalized IBD treatment strategies, particularly for athletes and individuals seeking complementary approaches to support both disease management and performance optimization.

Healthcare providers, athletes, and patients considering FIR therapy should approach this treatment as part of a comprehensive, multidisciplinary care plan that prioritizes safety, evidence-based practice, and individualized treatment goals. With continued research and clinical experience, far infrared therapy may prove to be a valuable addition to the therapeutic armamentarium for Crohn's Disease management in the 21st century.

References

Akasaki, Y., Miyata, M., Eto, H., Shirasawa, T., Hamada, N., Ikeda, Y., ... & Tei, C. (2006). Repeated thermal therapy up-regulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. Circulation Journal, 70(4), 463-470.

Avci, P., Gupta, A., Sadasivam, M., Vecchio, D., Pam, Z., Pam, N., & Hamblin, M. R. (2013). Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Seminars in Cutaneous Medicine and Surgery, 32(1), 41-52.

Beever, R. (2009). Far-infrared saunas for treatment of cardiovascular risk factors: summary of published evidence. Canadian Family Physician, 55(7), 691-696.

Boyapati, R. K., Tamborska, A., Dorward, D. A., & Ho, G. T. (2017). Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. F1000Research, 6, 169.

Chen, A. C. H., Arany, P. R., Huang, Y. Y., Tomkinson, E. M., Sharma, S. K., Kharkwal, G. B., ... & Hamblin, M. R. (2011). Low‐level laser therapy activates NF‐kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One, 6(7), e22453.

Chow, R. T., Johnson, M. I., Lopes-Martins, R. A., & Bjordal, J. M. (2009). Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. The Lancet, 374(9705), 1897-1908.

Clinical Trial (2023). The Assessment of Infrared Treatment for Crohn's Disease. Retrieved from https://ctv.veeva.com/study/the-assessment-of-infrared-treatment-for-crohns-disease

de Brito, A. A., da Silveira, E. C., Rigonato-Oliveira, N. C., Soares, S. S., Brandao-Rangel, M. A., Soares, C. R., ... & Vieira, R. P. (2016). Light-emitting diodes at 940 nm attenuate colitis-induced inflammatory process in mice. Journal of Photochemistry and Photobiology B: Biology, 162, 367-375.

Ernst, E., Pecho, E., Wirz, P., & Saradeth, T. (1990). Regular sauna bathing and the incidence of common colds. Annals of Medicine, 22(4), 225-227.

Hamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.

Hamblin, M. R. (2018). Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochemistry and Photobiology, 94(2), 199-212.

Hatoum, O. A., Binion, D. G., Otterson, M. F., & Gutterman, D. D. (2003). Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology, 125(1), 58-69.

Huang, Y. Y., Chen, A. C., Carroll, J. D., & Hamblin, M. R. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358-383.

Imam, T., Park, S., Kaplan, M. H., & Olson, M. R. (2018). Effector T helper cell subsets in inflammatory bowel diseases. Frontiers in Immunology, 9, 1212.

Imamura, M., Biro, S., Kihara, T., Yoshifuku, S., Takasaki, K., Otsuji, Y., ... & Tei, C. (2001). Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. Journal of the American College of Cardiology, 38(4), 1083-1088.

Kaplan, G. G. (2015). The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12(12), 720-727.

Karu, T. (1999). Primary and secondary mechanisms of action of visible to near-IR radiation on cells. Journal of Photochemistry and Photobiology B: Biology, 49(1), 1-17.

Khor, B., Gardet, A., & Xavier, R. J. (2011). Genetics and pathogenesis of inflammatory bowel disease. Nature, 474(7351), 307-317.

Kregel, K. C. (2002). Invited review: heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. Journal of Applied Physiology, 92(5), 2177-2186.

Lai, C. H., Chiang, T. M., Hsieh, C. L., Chang, C. H., Li, T. M., Liang, J. A., & Lin, J. G. (2020). Far-3infrared Ray-mediated Antioxidant Potentials are Important for Attenuating Psychotoxic Disorders. Current Pharmaceutical Design, 26(1), 4-15.

Lam, R. W., Levitt, A. J., Levitan, R. D., Enns, M. W., Morehouse, R., Michalak, E. E., & Tam, E. M. (2006). The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. American Journal of Psychiatry, 163(5), 805-812.

Leung, T. K., Chan, C. F., Lai, P. S., Yang, C. H., Hsu, C. Y., & Lin, Y. S. (2011). Inhibitory effects of far-infrared irradiation generated by mineral bioceramic material on murine melanoma cell growth. International Journal of Photoenergy, 2011, 685357.

Liebert, A., Capon, W., Pang, V., Vila, D., Bicknell, B., McLachlan, C., ... & Kiat, H. (2023). A Holistic Perspective on How Photobiomodulation May Influence Fatigue, Pain, and Depression in Inflammatory Bowel Disease: Beyond Molecular Mechanisms. Journal of Clinical Medicine, 12(10), 3366.

Lin, C. C., Yang, C. C., Hsiao, L. D., Chen, S. Y., & Yang, C. M. (2018). The effect of far infrared radiation therapy on inflammation regulation in lipopolysaccharide-induced peritonitis in mice. Experimental and Therapeutic Medicine, 16(3), 2791-2798.

Marques, M. M., Diniz, I. M. A., de Cara, S. P. H. M., Pedroni, A. C. F., Abe, G. L., D'Alpino, P. H. P., ... & Bussadori, S. K. (2020). Red light-emitting diode treatment improves tissue recovery in DSS-induced colitis in mice. Journal of Photochemistry and Photobiology B: Biology, 209, 111918.

Matsumoto, S., Shimodozono, M., Etoh, S., Miyata, R., & Kawahira, K. (2011). Effects of thermal therapy combining sauna therapy and underwater exercise in patients with fibromyalgia. Complementary Therapies in Clinical Practice, 17(3), 162-166.

Munford, R. S., & Tracey, K. J. (2002). Is severe sepsis a neuroendocrine disease? Molecular Medicine, 8(8), 437-442.

Neurath, M. F. (2014). Cytokines in inflammatory bowel disease. Nature Reviews Immunology, 14(5), 329-342.

Ohori, T., Nozawa, T., Ihori, H., Shida, T., Sobajima, M., Matsuki, A., ... & Inoue, H. (2012). Effect of repeated sauna treatment on exercise tolerance and endothelial function in patients with chronic heart failure. American Journal of Cardiology, 109(1), 100-104.

Oosterveld, F. G., Rasker, J. J., Floors, M., Landkroon, R., van Rennes, B., Zwijnenberg, J., ... & Koel, G. J. (2009). Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. Clinical Rheumatology, 28(1), 29-34.

Peplow, P. V., Chung, T. Y., & Baxter, G. D. (2010). Laser photobiomodulation of proliferation of cells in culture: a review of human and animal studies. Photomedicine and Laser Surgery, 28(S1), S3-S40.

Sanderson, I. R., Naik, S., & Walker-Smith, J. A. (2008). The role of photobiomodulation in inflammatory bowel disease. Inflammatory Bowel Diseases, 14(7), 963-971.

Shang, Y., Chen, N., Xu, M., Huang, K., Li, Y., Duan, J., ... & Zhang, H. (2013). The effects of low-level laser therapy on nitric oxide synthase expression and nitric oxide production in endothelial cells: implications for the prevention of atherosclerosis. Photomedicine and Laser Surgery, 31(8), 381-389.

Shui, S., Wang, X., Chiang, J. Y., & Zheng, L. (2015). Far-infrared therapy for cardiovascular, autoimmune, and other chronic health problems: A systematic review. Experimental Biology and Medicine, 240(10), 1257-1265.

Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn's disease. The Lancet, 389(10080), 1741-1755.

Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingsley, P. J., Gorden, D. L., McIntyre, J. O., ... & Marnett, L. J. (2020). Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Research, 80(11), 2186-2199.

Yu, S. Y., Chiu, J. H., Yang, S. D., Hsu, Y. C., Lui, W. Y., & Wu, C. W. (2006). Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Photodermatology, Photoimmunology & Photomedicine, 22(2), 78-86.

Zeissig, S., Bürgel, N., Günzel, D., Richter, J., Mankertz, J., Wahnschaffe, U., ... & Schulzke, J. D. (2007). Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut, 56(1), 61-72.